Jumping Before They Were Pushed – Kiadis And Aradigm Withdraw EU Filings
A Third Company, Actelion, Has Pulled An Indication Extension Request
Notice of the withdrawal of pan-EU marketing authorizations applications by Kiadis Pharma and Aradigm are noted in the agenda of the latest meeting of the European Medicines Agency's key scientific committee, the CHMP.
